Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02679950 · ClinicalTrials.gov registry record
Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse
A clinical trial of Neoplasms, Germ Cell and Embryonal, sponsored by Nasser Hanna.
- Completed
- Registry status
- 6
- Enrollment target
- 2
- Study locations
NCT02679950: Completed study of Neoplasms, Germ Cell and Embryonal, sponsored by Nasser Hanna.
NCT02679950 is a study of Neoplasms, Germ Cell and Embryonal that has completed, run by Nasser Hanna. The registered enrollment target is 6 participants. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02679950, a study of Neoplasms, Germ Cell and Embryonal, has completed, sponsored by Nasser Hanna.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
The current proposal is a pilot study. The Investigators plan to use next generation genome sequencing (NGGS) to define the molecular and genetic profiles of 3 cases of germ cell tumor (GCT) (with a component of yolk sac tumor) at the time of the initial diagnosis and 3 cases of late relapse GCT's, which are characterized by yolk sac tumor (and AFP secreting) predominant disease. Investigators seek to demonstrate the feasibility of obtaining tissue biopsies (either archived or new biopsy) and utilization of NGGS in studying the molecular and genetic relationships between GCT's (with a component of yolk sac tumor) at the time of diagnosis and GCT's at the time of late relapse. This study will also provide preliminary information on genetic alterations, which may be a hypothesis for generating another study.
Primary Outcome
Collection of tissue and blood samples from 6 patients for genomic testing
Conditions Studied
Interventions
- GENETIC Next generation genome sequencing
Study Locations (2)
Indiana
- Indiana University Health Hospital - Indianapolis
- Indiana University Health Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-11-20 |
| Est. Completion | 2017-04-25 |
What the finished NCT02679950 record still lists
NCT02679950 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 1 condition, with Neoplasms, Germ Cell and Embryonal appearing as the primary indexed condition, and to 1 intervention - of which Next generation genome sequencing is the first listed.
NCT02679950 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT02679950 about?
NCT02679950 is a clinical study titled "Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse". The current proposal is a pilot study. The Investigators plan to use next generation genome sequencing (NGGS) to define the molecular and genetic profiles of 3 cases of germ cell tumor (GCT) (with a component of yolk sac tumor) at the time of the initial diagnosis and 3 cases of late relapse GCT's, ...
What is the current status of trial NCT02679950?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2015-11-20. Estimated completion is 2017-04-25.
What conditions does trial NCT02679950 study?
This clinical trial studies the following conditions: Neoplasms, Germ Cell and Embryonal.
What interventions are being tested in trial NCT02679950?
The interventions under investigation include: Next generation genome sequencing (GENETIC).
Who is sponsoring clinical trial NCT02679950?
This trial is sponsored by Nasser Hanna, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02679950 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI